@Biocartis_

Idylla™ ctNRAS-BRAF-EGFR S492R Mutation Assay (RUO)

  

About 50% of all metastatic colorectal tumors (mCRC) harbor RAS mutations¹. The frequency of NRAS mutations in exons 2, 3 and 4 is around 5%¹. The frequency of BRAF mutations in mCRC is 8%¹.

 

Using liquid biopsies for NRAS testing is minimally invasive, fast and easy to perform and provides an excellent solution to study NRAS, BRAF and EGFR mutations in different cancer types like colorectal cancer and melanoma.

 

Discover the benefits of the Idylla™ ctNRAS-BRAF-EGFR S492R Mutation Assay - the easiest and fastest solution to implement liquid biopsy testing in your research.

 

References
¹ Jean-Yves Douillard, M.D., Ph.D., Kelly S. Oliner, Ph.D., Salvatore Siena, M.D., et al. Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer. N Engl J Med 2013;369:1023-34.

Highly standardized

The Idylla™ ctNRAS-BRAF-EGFR S492R Mutation Assay, performed on the Idylla™ System, is a molecular assay for the semi-quantitative detection of 18 mutations in codons 12, 13, 59, 61, 117, 146 of the NRAS gene, 5 mutations in codon 600 of the BRAF gene and 2 mutations in codon 492 of the EGFR gene.

 

The Idylla™ ctNRAS-BRAF-EGFR S492R Mutation Assay extracts and amplifies NRAS, BRAF and EGFR circulating tumor DNA (ctDNA) from 1 ml of plasma. The Assay is a sample-to-result real-time PCR, intended for use in research applications only.

 

Idylla™ ctNRAS-BRAF-EGFR S492R Mutation Assay is intended for Research Use Only.

 

For product availability in your country contact us via customerservice@biocartis.com

Idylla™ ctNRAS-BRAF-EGFR S492R Mutation Assay Downloads